

Coding Reference Guide Measurement Year 2024

Antidepressant Medication Management (AMM)



Measure Description

Members 18 years of age and older who were prescribed an antidepressant medication during the 12-month window beginning May 1, 2023 and ending on April 30, 2024 and had a diagnosis of major depression and remained on an antidepressant for the following timeframes:

Effective Acute Phase Treatment: Members who remained on an antidepressant medication for at least 84 treatment days (12 weeks) beginning on the Index Prescription Start Date (IPSD) through 114 days after the IPSD (115 total days). Treatment days are calculated to allow for a gap in medication treatment up to a total of 31 days to account for a washout period to change medication or treatment gaps to refill the same medication.

Effective Continuation Phase Treatment: Members who remained on an antidepressant medication for at least 180 treatment days (six months) beginning on the IPSD through 231 days after the IPSD (232 total days). Treatment days are calculated to allow for a gap in medication treatment up to a total of 52 days to account for a washout period to change medication or treatment gaps to refill the same medication.

Definitions

Intake Period: The 12-month window starting on May 1, 2023 and ending on April 30, 2024.

Index Prescription Start Date (IPSD): The earliest prescription dispensing date for an antidepressant medication where the date is in the intake period and there is a negative medication history.

Negative Medication History: A period of 105 days prior to the IPSD when the patient had no pharmacy claims for either new or refill prescriptions for an antidepressant medication.

Treatment Days: The actual number of calendar days covered with prescriptions within the specified measurement interval.

Antidepressant Medications:

MVP's drug formulary is located here: [Formularies and Prescription Drug Coverage | MVP Health Care](#)

Miscellaneous Antidepressants	Bupropion, Vilazodone, Vortioxetine
Monoamine Oxidase Inhibitors	Isocarboxazid, Phenelzine, Selegiline, Tranylcypromine

Phenylpiperazine Antidepressants	Nefazodone, Trazodone
Psychotherapeutic Combinations	Amitriptyline-chlordiazepoxide, Amitriptyline-perphenazine, Fluoxetine-olanzapine
SNRI Antidepressants	Desvenlafaxine, Duloxetine, Levomilnacipran, Venlafaxine
SSRI Antidepressants	Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline
Tetracyclic Antidepressants	Maprotiline, Mirtazapine
Tricyclic Antidepressants	Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin (>6mg), Imipramine, Nortriptyline, Protriptyline, Trimipramine
Major Depression	
Major Depression	ICD10: F32.0, F32.1, F32.2, F32.3, F32.4, F32.9, F33.0, F33.1, F33.2, F33.3, F33.41, F33.9
	SNOMED: 832007, 2618002, 14183003, 15193003, 15639000, 18818009, 20250007, 25922000, 28475009, 33078009, 33736005, 36474008, 36923009, 38694004, 39809009, 40379007, 42925002, 60099002, 63778009, 66344007, 69392006, 71336009, 73867007, 75084000, 76441001, 77911002, 79298009, 87512008, 191604000, 191610000, 191611001, 191613003, 268621008, 319768000, 320751009, 370143000, 430852001, 450714000, 719592004, 720451004, 720452006, 720453001, 720454007, 720455008, 726772006, 251000119105, 281000119103, 10811121000119102, 10811161000119107, 16264621000119109, 16264821000119108, 16264901000119109, 16265951000119109, 16266831000119100, 16266991000119108
The following will exclude the Member from this measure and must occur during 2024:	
Hospice Encounter During 2024	HCPCS: G9473, G9474, G9475, G9476, G9477, G9478, G9479, Q5003, Q5004, Q5005, Q5006, Q5007, Q5008, Q5010, S9126, T2042, T2043, T2044, T2045, T2046
	SNOMED: 183919006, 183920000, 183921001, 305336008, 305911006, 385765002
	UBREV: 0115, 0125, 0135, 0145, 0155, 0235, 0650, 0651, 0652, 0655, 0656, 0657, 0658, 0659

Hospice Intervention During 2024	CPT: 99377, 99378
	HCPCS: G0182
	SNOMED: 170935008, 170936009, 385763009
Patients who died any time during 2024	

Tips and Best Practices to Help Improve Performance

- Include the following topics in your discussions with patients who are prescribed antidepressant medications:
 - When will the medication start working and how will the patient know that it's working
 - What will it feel like to be on the medication
 - How long will the patient need to be on the medication
 - What are the possible side effects and what should be done if they occur
 - What to do about missed doses
 - Importance of continuing the medication even if the patient is feeling better
 - Importance of follow-up visits
- Elderly patients may benefit from the help of family members who can assist with medication cueing, set-up of pill organizers, drug charts, reminder calls, etc.
- Stock patient areas and exam rooms with educational materials such as those found here:
 - [Mental Health | CDC](#)
 - [Behavioral Health - MVP Health Care](#)
- Call MVP Customer Care Center for Provider Services at 1-800-684-9286 for case management guidance, home care referrals, and other community support available to assist patients and their families